Plasma insulin-like growth factor I levels during treatment of congenital adrenal hyperplasia

Anita Cavallo, Richard W. Furlanetto, Walter J. Meyėr

Research output: Contribution to journalArticle

3 Scopus citations


We tested the hypotheses that the levels of insulin-like growth factor I (IGF-I) reflect the degree of control during the treatment of patients with congenital adrenal hyperplasia (CAH), and that suppressed IGF-I levels during puberty contribute to decreased adult height. We measured serial IGF-I levels in 26 CAH patients followed over 6 months to 5 years. The control of CAH was variable, with several cases of overtreatment in infancy, and frequent undertreatment in childhood and adolescence. IGF-I levels were quite variable and inconsistent with the control of CAH. Our results suggest that IGF-I levels are not helpful in monitoring CAH patients; IGF-I does not seem to play a role in the growth failure during CAH therapy.

Original languageEnglish (US)
Pages (from-to)23-26
Number of pages4
JournalHormone Research in Paediatrics
Issue number1
StatePublished - Jan 1 1990



  • Congenital adrenal hyperplasia
  • Growth
  • Insulin-like growth factor I

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this